Mark Cushman
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
315
Citations
9,882
Est. group size
~1
Recurring co-author estimate
Active years
55
Publishing since 1971
Mark Cushman's research focuses on designing and testing new chemical compounds, particularly indenoisoquinolines, that target enzymes like topoisomerase I to fight cancer. His work involves synthesizing these molecules and studying how they interact with DNA and cellular proteins to overcome drug resistance in cancer cells. This research sits at the intersection of chemistry and cancer biology, aiming to develop improved cancer therapeutics.
Publication output was relatively steady from 2017-2019, dropped sharply from 2020-2022, then spiked dramatically in 2023 before tapering off again, suggesting an irregular rather than steadily growing or declining pattern.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 3103: Dual targeting MYC G-quadruplex and topoisomerase I by indenoisoquinolines for cancer therapy
Cancer Research · 2023
- Data from Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance
2023
- Data from Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance
2023
- Supplementary Figure 1 from Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance
2023
- Supplementary Figure 2 from Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance
2023
- Supplementary Legends 1-2 from Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance
2023
- Supplementary Legends 1-2 from Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance
2023
- Supplementary Figure 1 from Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance
2023
- Supplementary Figure 2 from Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance
2023
- Table S2 from Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
2023
- Figure S1 from Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
2023
- Table S4 from Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
2023
- Table S3 from Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
2023
- Figure S2 from Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
2023
- Table S1 from Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
2023
- Journal of Medicinal Chemistry×8
- European Journal of Medicinal Chemistry×4
- Cancer Research×4
- Bioorganic & Medicinal Chemistry×2
- Journal of the American Chemical Society×1
- Jack C. Yalowich
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Chelsea A. Mann
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Yanran Lu
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Mark J. Mitton‐Fry
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Daniel E. Beck
Pharmacology, Toxicology and Pharmaceutics · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile